CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Results showed that primary CD34+ cells from four CML samples (CML-2, CML-3, CML-4, and CML-5) responded well to GSI treatment, which was evident by significant (p<0.05) downregulation of Hes1 (Fig 5a).